Atlantic Coastal Acquisition Corp. II Completes Business Combination with Abpro Corporation

Big Cypress Acquisition Corp. Completes Business Combination with SAB Biotherapeutics

October 20, 2021

Biotechnology

Big Cypress Acquisition Corp., a Nasdaq-listed special purpose acquisition company, received shareholder approval to complete a business combination with clinical-stage biopharmaceutical company SAB Biotherapeutics. Upon closing, the combined company will be named SAB Biotherapeutics, Inc. and its common stock and warrants are expected to trade on Nasdaq, providing SAB with public-market capital to advance its antibody immunotherapy platform and clinical programs.

Avista SPAC (APAC) to Combine with Ligand's OmniAb in Spin-off and Business Combination

October 24, 2022

Biotechnology

Ligand Pharmaceuticals will spin off its OmniAb antibody discovery business to shareholders and OmniAb will merge with Avista Public Acquisition Corp. II (APAC), making OmniAb a standalone, publicly-traded company. Avista Capital Partners has committed up to $115 million of investment and Ligand will contribute $15 million, providing the combined company with significant cash reserves to support growth and continued platform development.

Pacific Biosciences Acquires Apton Biosystems

August 2, 2023

Biotechnology

Pacific Biosciences (PacBio) has entered into an agreement to acquire Apton Biosystems, a Pleasanton, California-based developer of high-throughput short-read sequencing instrumentation, to accelerate development of a next-generation, high-throughput short-read sequencer. The all-stock deal provides approximately $85 million upfront (≈6.3M shares) plus up to $25 million in additional consideration contingent on achieving $50 million in revenue, valuing the transaction at up to ~$110 million.

Astellas Pharma Acquires Propella Therapeutics

November 15, 2023

Biotechnology

Astellas Pharma, through its U.S. subsidiary Astellas US Holding, agreed to acquire privately held biopharmaceutical company Propella Therapeutics for approximately US$175 million. The acquisition gives Astellas ownership of PRL-02, a next-generation long-acting abiraterone prodrug for prostate cancer currently in Phase 1, and is expected to close within Astellas' fiscal year 2023 (ending March 31, 2024).

AbbVie Acquires Capstan Therapeutics

August 19, 2025

Biotechnology

AbbVie has completed its acquisition of Capstan Therapeutics, adding Capstan's lead asset CPTX2309 — an in vivo targeted lipid nanoparticle (tLNP) anti‑CD19 CAR‑T candidate in Phase 1 for B cell‑mediated autoimmune diseases — and a proprietary tLNP RNA delivery platform. The deal strengthens AbbVie's immunology pipeline and expands its in vivo cell‑programming capabilities for RNA payload delivery.

Danaher Corporation Acquires Abcam plc

August 28, 2023

Biotechnology

Danaher Corporation agreed to acquire Abcam plc for $24.00 per share, representing an enterprise value of approximately $5.7 billion including assumed indebtedness. Abcam, headquartered in Cambridge, United Kingdom, will operate as a standalone company within Danaher's Life Sciences segment; the transaction is expected to close in mid-2024 and is subject to customary approvals.